Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3130120 | 0.94 | USP30 (0.37) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL3136405 | 0.94 | USP30 (0.37) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL3130127 | 0.94 | USP30 (0.37) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL3134744 | 0.87 | NR1H2 (0.47) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL3127629 | 0.86 | NPC1 (0.42) | USP30LIPEGPR119 | |
| SCHEMBL3127634 | 0.86 | NPC1 (0.42) | USP30LIPEGPR119 | |
| SCHEMBL3138054 | 0.83 | MAPT (0.53) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL3127706 | 0.81 | NR1H2 (0.43) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL3136845 | 0.81 | NR1H2 (0.43) | ESR2USP30NR1H2LIPEGPR119 | |
| SCHEMBL5421540 | 0.79 | USP30 (0.41) | ESR2USP30NR1H2GPR119PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399445-B9 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1399445-B1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-05 | — | — | EP | disclosed |
| US-6777406-B2 | SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092502-A1 | SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS | HTR1B, HTR2B, HTR1A | ESR2 2912/4885USP30 4353/4885NR1H2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.